FullText URL | fulltext.pdf |
---|---|
Author | Makimoto, Go| Shimonishi, Atsushi| Ohashi, Kadoaki| Ninomiya, Kiichiro| Higo, Hisao| Kato, Yuka| Fujii, Masanori| Kubo, Toshio| Ichihara, Eiki| Hotta, Katsuyuki| Tabata, Masahiro| Maeda, Yoshinobu| Kiura, Katsuyuki| |
Keywords | MET Tepotinib Non-small-cell lung cancer |
Published Date | 2022 |
Publication Title | Case Reports In Oncology |
Volume | volume15 |
Issue | issue2 |
Publisher | Karger |
Start Page | 494 |
End Page | 498 |
ISSN | 1662-6575 |
Content Type | Journal Article |
language | English |
OAI-PMH Set | 岡山大学 |
Copyright Holders | © 2022 The Author(s). |
File Version | publisher |
PubMed ID | 35702678 |
DOI | 10.1159/000524326 |
Web of Science KeyUT | 000864085100005 |
Related Url | isVersionOf https://doi.org/10.1159/000524326 |
FullText URL | fulltext.pdf figs.pdf tables.pdf |
---|---|
Author | Itano, Junko| Higo, Hisao| Ohashi, Kadoaki| Makimoto, Go| Nishii, Kazuya| Hotta, Katsuyuki| Miyahara, Nobuaki| Maeda, Yoshinobu| Kiura, Katsuyuki| |
Keywords | osimertinib drug-induced ILD reversed halo sign organizing pneumonia pattern re-administration |
Published Date | 2020-03-15 |
Publication Title | Internal Medicine |
Volume | volume59 |
Issue | issue6 |
Publisher | The Japanese Society of Internal Medicine |
Start Page | 823 |
End Page | 828 |
ISSN | 0918-2918 |
NCID | AA10827774 |
Content Type | Journal Article |
language | English |
OAI-PMH Set | 岡山大学 |
Copyright Holders | © 2020 by The Japanese Society of Internal Medicine |
File Version | author |
PubMed ID | 31787696 |
DOI | 10.2169/internalmedicine.3689-19 |
Web of Science KeyUT | 000521137500011 |
Related Url | isVersionOf https://doi.org/10.2169/internalmedicine.3689-19 |
Author | Kubo, Toshio| Takigawa, Nagio| Osawa, Masahiro| Harada, Daijiro| Ninomiya, Takashi| Ochi, Nobuaki| Ichihara, Eiki| Yamane, Hiromichi| Tanimoto, Mitsune| Kiura, Katsuyuki| |
---|---|
Published Date | 2013-01 |
Publication Title | Cancer Science |
Volume | volume104 |
Issue | issue1 |
Content Type | Journal Article |
JaLCDOI | 10.18926/AMO/54514 |
---|---|
FullText URL | 70_4_327.pdf |
Author | Watanabe, Mototsugu| Yamamoto, Hiromasa| Eikawa, Shingo| Shien, Kazuhiko| Shien, Tadahiko| Soh, Junichi| Hotta, Katsuyuki| Wada, Jun| Hinotsu, Shiro| Fujiwara, Toshiyoshi| Kiura, Katsuyuki| Doihara, Hiroyoshi| Miyoshi, Shinichiro| Udono, Heiichiro| Toyooka, Shinichi| |
Abstract | A study to evaluate the effect of metformin on the immune system was commenced in July 2014. Metformin is one of the most commonly prescribed drugs for type 2 diabetes, and previous studies have reported that metformin has an anti-tumor effect. The aim of this study is to evaluate the efficacy of metformin on the immune system in human cancer patients in vivo. The primary outcome parameter will be the rate change in the population of CD8+ T cells, which produce multiple cytokines. |
Keywords | metformin CD8+ T cells cancer immunology |
Amo Type | Clinical Study Protocols |
Publication Title | Acta Medica Okayama |
Published Date | 2016-08 |
Volume | volume70 |
Issue | issue4 |
Publisher | Okayama University Medical School |
Start Page | 327 |
End Page | 330 |
ISSN | 0386-300X |
NCID | AA00508441 |
Content Type | Journal Article |
language | English |
Copyright Holders | CopyrightⒸ 2016 by Okayama University Medical School |
File Version | publisher |
Refereed | True |
PubMed ID | 27549683 |
Web of Science KeyUT | 000384748600018 |
Author | Ueno, Tsuyoshi| Tsukuda, Kazunori| Toyooka, Shinichi| Ando, Midori| Takaoka, Munenori| Soh, Junichi| Asano, Hiroaki| Maki, Yuho| Muraoka, Takayuki| Tanaka, Norimitsu| Shien, Kazuhiko| Furukawa, Masashi| Yamatsuji, Tomoki| Kiura, Katsuyuki| Naomoto, Yoshio| Miyoshi, Shinichiro| |
---|---|
Published Date | 2012-04 |
Publication Title | Lung Cancer |
Volume | volume76 |
Issue | issue1 |
Content Type | Journal Article |
Author | Ochi, Nobuaki| Takigawa, Nagio| Harada, Daijiro| Yasugi, Masayuki| Ichihara, Eiki| Hotta, Katsuyuki| Tabata, Masahiro| Tanimoto, Mitsune| Kiura, Katsuyuki| |
---|---|
Published Date | 2014-03-10 |
Publication Title | Experimental Cell Research |
Volume | volume322 |
Issue | issue1 |
Content Type | Journal Article |
JaLCDOI | 10.18926/AMO/30737 |
---|---|
FullText URL | fulltext.pdf |
Author | Suzaki, Noriyuki| Hiraki, Akio| Takigawa, Nagio| Ueoka, Hiroshi| Tanimoto, Yasushi| Kozuki, Toshiyuki| Tabata, Masahiro| Kanehiro, Arihiko| Kiura, Katsuyuki| Tanimoto, Mitsune| |
Abstract | A 71-year-old Japanese man with adenocarcinoma of the lung developed interstitial pneumonia after treatment with paclitaxel. The patient had acute chills and fever on the fourth day after the second exposure to paclitaxel, rapidly got worse despite empiric therapies, and developed prolonged respiratory failure requiring mechanical ventilation. Four months later, he died of respiratory failure due to progression of both interstitial pneumonia and lung cancer. This is the first case developing fatal paclitaxel-induced pulmonary toxicity to date. Interstitial pneumonia should be considered one of the possible life-threatening complications during treatment with paclitaxel. |
Keywords | paclitaxel adverse effect lung cancer interstitial pneumonia |
Amo Type | Article |
Publication Title | Acta Medica Okayama |
Published Date | 2006-10 |
Volume | volume60 |
Issue | issue5 |
Publisher | Okayama University Medical School |
Start Page | 295 |
End Page | 298 |
ISSN | 0386-300X |
NCID | AA00508441 |
Content Type | Journal Article |
language | English |
File Version | publisher |
Refereed | True |
PubMed ID | 17072376 |
Web of Science KeyUT | 000241509000006 |
JaLCDOI | 10.18926/AMO/48564 |
---|---|
FullText URL | 66_3_245.pdf |
Author | Okada, Toshiaki| Takigawa, Nagio| Kishino, Daizo| Katayama, Hideki| Kuyama, Shouichi| Sato, Ken| Mimoto, Junko| Ueoka, Hiroshi| Tanimoto, Mitsune| Kiura, Katsuyuki| |
Abstract | Cisplatin is used to treat lung cancer;however, it is also a known carcinogen. Cyclooxygenase-2 (COX-2) inhibitors have been shown to prevent carcinogen-induced experimental tumors. We investigated the effect of a COX-2 inhibitor, celecoxib, on cisplatin-induced lung tumors. One hundred twenty 4-week-old A/J mice were divided into 6 groups:group 1, no treatment;group 2, low-dose celecoxib (150mg/kg);group 3, high-dose celecoxib (1,500mg/kg);group 4, cisplatin alone;group 5, cisplatin plus low-dose celecoxib;and group 6, cisplatin plus high-dose celecoxib. Mice in groups 4-6 were administered cisplatin (1.62mg/kg, i.p.) once a week for 10 weeks between 7 and 16 weeks of age. All mice were sacrificed at week 30. Tumor incidence was 15.8% in group 1, 25% in group 2, 26.3% in group 3, 60% in group 4, 50% in group 5, and 50% in group 6. Tumor multiplicity was 0.2, 0.3, 0.3, 1.3, 1.0, and 0.6 in groups 1-6, respectively. Tumor multiplicity in the cisplatin-treated mice was reduced by celecoxib treatment in a dose-dependent manner (p<0.05, group 4 vs. group 6). Celecoxib significantly reduced COX-2 expression in cisplatin-induced tumors (p<0.01, group 4 vs. group 6). |
Keywords | cisplatin non-small cell lung cancer celecoxib cyclooxygenase-2 chemoprevention |
Amo Type | Original Article |
Publication Title | Acta Medica Okayama |
Published Date | 2012-06 |
Volume | volume66 |
Issue | issue3 |
Publisher | Okayama University Medical School |
Start Page | 245 |
End Page | 251 |
ISSN | 0386-300X |
NCID | AA00508441 |
Content Type | Journal Article |
language | English |
Copyright Holders | CopyrightⒸ 2012 by Okayama University Medical School |
File Version | publisher |
Refereed | True |
PubMed ID | 22729105 |
Web of Science KeyUT | 000305669700008 |
FullText URL | fulltext.pdf |
---|---|
Author | Sugiura, Hiroyuki| Nishimori, Hisakazu| Nishii, Kazuya| Toji, Tomohiro| Fujii, Keiko| Fujii, Nobuharu| Matsuoka, Ken-ichi| Nakata, Koh| Kiura, Katsuyuki| Maeda, Yoshinobu| |
Keywords | pulmonary alveolar proteinosis primary myelofibrosis autopsy ruxolitinib |
Published Date | 2020-08-15 |
Publication Title | Internal Medicine |
Volume | volume59 |
Issue | issue16 |
Start Page | 2023 |
End Page | 2028 |
ISSN | 0918-2918 |
NCID | AA10827774 |
Content Type | Journal Article |
language | English |
OAI-PMH Set | 岡山大学 |
Copyright Holders | © 2020 by The Japanese Society of Internal Medicine |
File Version | publisher |
PubMed ID | 32448830 |
DOI | 10.2169/internalmedicine.4082-19 |
Web of Science KeyUT | 000563078400014 |
Related Url | isVersionOf https://doi.org/10.2169/internalmedicine.4082-19 |
FullText URL | fulltext.pdf |
---|---|
Author | Katsui, Kuniaki| Ogata, Takeshi| Sugiyama, Soichi| Yoshio, Kotaro| Kuroda, Masahiro| Hiraki, Takao| Kiura, Katsuyuki| Maeda, Yoshinobu| Toyooka, Shinichi| Kanazawa, Susumu| |
Published Date | 2021-06-04 |
Publication Title | scientific reports |
Volume | volume11 |
Issue | issue1 |
Publisher | Nature Research |
Start Page | 11882 |
ISSN | 2045-2322 |
Content Type | Journal Article |
language | English |
OAI-PMH Set | 岡山大学 |
Copyright Holders | © The Author(s) 2021 |
File Version | publisher |
PubMed ID | 34088965 |
DOI | 10.1038/s41598-021-91449-z |
Web of Science KeyUT | 000678611200010 |
Related Url | isVersionOf https://doi.org/10.1038/s41598-021-91449-z |
JaLCDOI | 10.18926/AMO/30751 |
---|---|
FullText URL | fulltext.pdf |
Author | Kitajima, Takuji| Nishii, Kenji| Ueoka, Hiroshi| Shibayama, Takuo| Gemba, Kenichi| Kodani, Tsuyoshi| Kiura, Katsuyuki| Tabata, Masahiro| Hotta, Katsuyuki| Tanimoto, Mitsune| Sobue, Tomotaka| |
Abstract | To evaluate recent improvements in lung cancer screening, we compared the results of recently conducted lung cancer screening with those of a previous screening. This study compared the survival of lung cancer patients detected by lung cancer screening conducted between 1976 and 1984 (early period) with that conducted between 1989 and 1997 (late period). Two hundred seventy-six patients with lung cancer were detected in the early period and 541 patients with lung cancer were detected in the late period. The median survival time (late : 49.8 vs. early : 27.8 months) and the 5-year survival rate (late : 47.8 vs. early : 34.8%) of the patients with lung cancer detected in the late period were significantly better than those in the early period (p = 0.0054). Among patients undergoing resection, the proportion of pathological stage I patients in the late period was significantly higher than that in the early period (late : 60.8 vs. early : 54.9%, p = 0.005). Multivariate analysis showed that the screening time period was a significant prognostic factor (hazard ratio = 0.685, 95% confidence interval : 0.563-0.832, p = 0.0002). These results were consistent with the findings of case-control studies of lung cancer screening programs in the late period recently conducted in Japan, which also showed a greater efficacy for screening than for previous case-control studies in the early period. |
Keywords | lung cancer screening survival lung cancer mortality |
Amo Type | Article |
Publication Title | Acta Medica Okayama |
Published Date | 2006-06 |
Volume | volume60 |
Issue | issue3 |
Publisher | Okayama University Medical School |
Start Page | 173 |
End Page | 179 |
ISSN | 0386-300X |
NCID | AA00508441 |
Content Type | Journal Article |
language | English |
File Version | publisher |
Refereed | True |
PubMed ID | 16838046 |
Web of Science KeyUT | 000238503600005 |
JaLCDOI | 10.18926/AMO/60802 |
---|---|
FullText URL | 74_5_423.pdf |
Author | Hirabae, Atsuko| Ichihara, Eiki| Sunami, Ryota| Ota, Moeko| Iwamoto, Yoshitaka| Maeda, Yoshinobu| Kiura, Katsuyuki| |
Abstract | We report a case of late-onset hyperprogressive disease after cessation of a PD-1 inhibitor. A male was diagnosed with metastatic lung adenocarcinoma with little progression for 2 months before treatment. He received pembrolizumab as a second-line treatment and was subsequently prescribed docetaxel for 3 months until a slight increase in pleural effusion. At the time of progression to docetaxel, he commenced prednisolone because of immune-system-related diarrhea. After that, his general condition rapidly worsened with severe fatigue and hypoxia. Computed tomography revealed a massive increase of pleural effusion and replacement of almost the entire liver with cancer over a period of 5 weeks. |
Keywords | lung cancer immune checkpoint inhibitors pembrolizumab hyperprogression |
Amo Type | Case Report |
Publication Title | Acta Medica Okayama |
Published Date | 2020-10 |
Volume | volume74 |
Issue | issue5 |
Publisher | Okayama University Medical School |
Start Page | 423 |
End Page | 425 |
ISSN | 0386-300X |
NCID | AA00508441 |
Content Type | Journal Article |
language | English |
Copyright Holders | CopyrightⒸ 2020 by Okayama University Medical School |
File Version | publisher |
Refereed | True |
PubMed ID | 33106698 |
Web of Science KeyUT | 000581970100007 |
NAID | 120006892928 |
FullText URL | J_Thorac_Oncol_201907017.pdf |
---|---|
Author | Makimoto, Go| Ohashi, Kadoaki| Tomida, Shuta| Nishii, Kazuya| Matsubara, Takehiro| Kayatani, Hiroe| Higo, Hisao| Ninomiya, Kiichiro| Sato, Akiko| Watanabe, Hiromi| Kano, Hirohisa| Ninomiya, Takashi| Kubo, Toshio| Rai, Kammei| Ichihara, Eiki| Hotta, Katsuyuki| Tabata, Masahiro| Toyooka, Shinichi| Takata, Minoru| Maeda, Yoshinobu| Kiura, Katsuyuki| |
Keywords | ALK G1202R Alectinib Amphiregulin MET NSCLC |
Published Date | 2019-07-30 |
Publication Title | Journal of Thoracic Oncology |
Volume | volume14 |
Issue | issue11 |
Publisher | Elsevier |
Start Page | 2009 |
End Page | 2018 |
ISSN | 15560864 |
NCID | AA12058455 |
Content Type | Journal Article |
language | English |
OAI-PMH Set | 岡山大学 |
Copyright Holders | © 2019 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved. |
File Version | author |
PubMed ID | 31374369 |
DOI | 10.1016/j.jtho.2019.07.017 |
Web of Science KeyUT | 000492678300025 |
Related Url | isVersionOf https://doi.org/10.1016/j.jtho.2019.07.017 |
FullText URL | fulltext.pdf |
---|---|
Author | Katsui, Kuniaki| Ogata, Takeshi| Watanabe, Kenta| Katayama, Norihisa| Kuroda, Masahiro| Kiura, Katsuyuki| Hiraki, Takao| Maeda, Yoshinobu| Toyooka, Shinichi| Kanazawa, Susumu| |
Keywords | cisplatin docetaxel dose-volume histogram non-small cell lung cancer PACIFIC trial radiation pneumonitis |
Published Date | 2020-05-04 |
Publication Title | Cancer Medicine |
Publisher | Wiley |
ISSN | 2045-7634 |
Content Type | Journal Article |
language | English |
OAI-PMH Set | 岡山大学 |
Copyright Holders | © 2020 The Authors. |
File Version | publisher |
PubMed ID | 32364685 |
DOI | 10.1002/cam4.3093 |
Web of Science KeyUT | 000530411600001 |
Related Url | isVersionOf https://doi.org/10.1002/cam4.3093 |
FullText URL | fulltext.pdf |
---|---|
Author | Sugimoto, Seiichiro| Soh, Junichi| Suzawa, Ken| Miyoshi, Kentaroh| Otani, Shinji| Yamamoto, Hiromasa| Okazaki, Mikio| Yamane, Masaomi| Oto, Takahiro| Kanazawa, Susumu| Kiura, Katsuyuki| Toyooka, Shinichi| |
Keywords | Lung cancer Aspergillosis Surgery Radiation Chemotherapy |
Note | This is a post-peer-review, pre-copyedit version of an article published in Surgery Today. The final authenticated version is available online at: http://dx.doi.org/10.1007/s00595-020-01960-5.| |
Published Date | 2020-01-21 |
Publication Title | Surgery Today |
Volume | volume50 |
Issue | issue8 |
Publisher | Springer |
Start Page | 863 |
End Page | 871 |
ISSN | 0941-1291 |
NCID | AA10824685 |
Content Type | Journal Article |
language | English |
OAI-PMH Set | 岡山大学 |
File Version | author |
PubMed ID | 31965262 |
DOI | 10.1007/s00595-020-01960-5 |
Web of Science KeyUT | 000550244700010 |
Related Url | isVersionOf https://doi.org/10.1007/s00595-020-01960-5 |
FullText URL | fulltext.pdf |
---|---|
Author | Ando, Eri| Nakasuka, Takamasa| Kubo, Toshio| Taniguchi, Akihiko| Ninomiya, Kiichiro| Kato, Yuka| Ichihara, Eiki| Ohashi, Kadoaki| Rai, Kammei| Hotta, Katsuyuki| Yamane, Masaomi| Miyahara, Nobuaki| Tabata, Masahiro| Maeda, Yoshinobu| Kiura, Katsuyuki| |
Keywords | pulmonary aspergilloma allergic bronchopulmonary aspergillosis disaster |
Published Date | 2022-02-01 |
Publication Title | Internal Medicine |
Volume | volume61 |
Issue | issue3 |
Publisher | JAPAN SOC INTERNAL MEDICINE |
Start Page | 379 |
End Page | 383 |
ISSN | 0918-2918 |
NCID | AA10827774 |
Content Type | Journal Article |
language | English |
OAI-PMH Set | 岡山大学 |
Copyright Holders | © 2022 The Japanese Society of Internal Medicine |
File Version | publisher |
PubMed ID | 34373373 |
DOI | 10.2169/internalmedicine.7124-21 |
Web of Science KeyUT | 000752787300015 |
Related Url | isVersionOf https://doi.org/10.2169/internalmedicine.7124-21 |
JaLCDOI | 10.18926/AMO/55446 |
---|---|
FullText URL | 71_5_453.pdf |
Author | Taniguchi, Akihiko| Miyahara, Nobuaki| Oda, Naohiro| Morichika, Daisuke| Ichihara, Eiki| Oze, Isao| Tanimoto, Yasushi| Ichikawa, Hirohisa| Fujii, Utako| Tanimoto, Mitsune| Kanehiro, Arihiko| Kiura, Katsuyuki| |
Abstract | Although recent retrospective studies suggested that the use of β-blockers appears to help improve the mortality rate and decrease the rate of exacerbation in chronic obstructive pulmonary disease (COPD) patients with heart failure, the effects of β-blockers on COPD patients without heart failure have not been established. Based on previous reports, we have launched a multicenter, prospective, single-arm phase II study to evaluate the preventive effect of the cardioselective β-blocker bisoprolol in COPD exacerbation, in Japanese individuals with moderate-to-severe COPD who do not have heart failure but do have hypertension requiring the use of medication. The primary endpoint is the rate of mild-to-severe COPD exacerbation. The results of this study will clarify whether bisoprolol can prevent exacerbation in COPD patients without heart failure. |
Keywords | chronic obstructive pulmonary disease β-blocker bisoprolol exacerbation heart failure |
Amo Type | Clinical Study Protocol |
Publication Title | Acta Medica Okayama |
Published Date | 2017-10 |
Volume | volume71 |
Issue | issue5 |
Publisher | Okayama University Medical School |
Start Page | 453 |
End Page | 457 |
ISSN | 0386-300X |
NCID | AA00508441 |
Content Type | Journal Article |
language | English |
Copyright Holders | CopyrightⒸ 2017 by Okayama University Medical School |
File Version | publisher |
Refereed | True |
PubMed ID | 29042706 |
Author | Shien, Kazuhiko| Toyooka, Shinichi| Ichimura, Kouichi| Soh, Junichi| Furukawa, Masashi| Maki, Yuho| Muraoka, Takayuki| Tanaka, Norimitsu| Ueno, Tsuyoshi| Asano, Hiroaki| Tsukuda, Kazunori| Yamane, Masaomi| Oto, Takahiro| Kiura, Katsuyuki| Miyoshi, Shinichiro| |
---|---|
Published Date | 2012-07 |
Publication Title | Lung Cancer |
Volume | volume77 |
Issue | issue1 |
Content Type | Journal Article |
JaLCDOI | 10.18926/AMO/31310 |
---|---|
FullText URL | fulltext.pdf |
Author | Tamura, Makoto| Ueoka, Hiroshi| Kiura, Katsuyuki| Tabata, Masahiro| Shibayama, Takuo| Miyatake, Kazuyo| Genba, Kenichi| Hiraki, Shunkichi| harada, Mine| |
Abstract | In order to elucidate factors influencing the prognosis of small-cell lung cancer (SCLC), we reviewed the records of 253 patients with SCLC and evaluated 20 pretreatment prognostic factors by univariate analysis and Cox's multiple regression analysis. Recursive partitioning and amalgamation (RPA) was employed to identify subgroups with similar survival rates. Cox's multiple regression analysis identified five significant factors: extent of disease, number of metastatic sites, serum albumin, serum lactate dehydrogenase, and presence of weight loss. Among these, extent of disease was the most influential factor. RPA analysis revealed three subgroups predicting significantly different prognoses. The median survival time and 3-year survival rate were 18.4 months and 20.6%, respectively for the good-risk group (limited disease without weight loss), 13.5 months and 9.1%, respectively for the intermediate-risk group (limited disease with weight loss or extensive disease with less than two metastatic sites), and 9.2 months and 0%, respectively for the poor-risk group (extensive disease with two or more metastatic sites). These results will be useful for development of new staging system or subsequent stratification for randomized trials. |
Keywords | prognostic factors Cox's multiple regression analysis recursive partitioning and amalgamayion method small-sell lung canser |
Amo Type | Article |
Publication Title | Acta Medica Okayama |
Published Date | 1998-04 |
Volume | volume52 |
Issue | issue2 |
Publisher | Okayama University Medical School |
Start Page | 105 |
End Page | 111 |
ISSN | 0386-300X |
NCID | AA00508441 |
Content Type | Journal Article |
language | English |
File Version | publisher |
Refereed | True |
PubMed ID | 9588226 |
Web of Science KeyUT | 000073363000006 |
FullText URL | fulltext.pdf |
---|---|
Author | Kuribayashi, Tadahiro| Kinoshita, Rie| Ninomiya, Kiichiro| Makimoto, Go| Kubo, Toshio| Rai, Kammei| Ichihara, Eiki| Hotta, Katsuyuki| Tabata, Masahiro| Maeda, Yoshinobu| Kiura, Katsuyuki| Toyooka, Shinichi| Sakaguchi, Masakiyo| Ohashi, Kadoaki| |
Keywords | S100A8/A9 Lung cancer Immune checkpoint inhibitors |
Note | The version of record of this article, first published in Scientific Reports, is available online at Publisher’s website: http://dx.doi.org/10.1038/s41598-025-87232-z| |
Published Date | 2025-01-20 |
Publication Title | Scientific Reports |
Volume | volume15 |
Issue | issue1 |
Publisher | Nature Portfolio |
Start Page | 2577 |
ISSN | 2045-2322 |
Content Type | Journal Article |
language | English |
OAI-PMH Set | 岡山大学 |
Copyright Holders | © The Author(s) 2025 |
File Version | publisher |
PubMed ID | 39833332 |
DOI | 10.1038/s41598-025-87232-z |
Web of Science KeyUT | 001400880600002 |
Related Url | isVersionOf https://doi.org/10.1038/s41598-025-87232-z |